Yissum - Research Development Company of the Hebrew University posted this:Novel Autotaxin Inhibitor Drug for the treatment of Cancer and Asthma (XIIPHONATE)Cluster8 We propose a novel compound for the treatment of asthma. We suggest to use this new compound named XIIPHONATE as new lipid-mimetic molecule that inhibits recombinant Autotaxin (ATX), as a potential local, long-term treatment for asthma. This approach is based on the fact that a novel bioactive lipid mediator, Lysophosphatidic acid (LPA), has a pivotal role in the pathogenesis of asthma. It was reported that LPA is synthesized from LPC through the enzymatic activity of ATX. Clinical data show that the levels of ATX protein, and LPA are significantly elevated the in airspaces of patients with asthma. Thus, XIIPHONATE, will inhibit LPA overproduction that leads to the pathologic state. It will therefore present a new therapeutic modality for asthma. Project ID : 6-2016-4268
Small and Medium Enterprise
Creative Biogene posted this:Human HTR2B-FLAG Stable Cell Line-CHO5-HT2B (5-hydroxytryptamine receptor 2B) is a receptor for serotonin. It is expressed in many peripheral and central nervous system tissues, including stomach fundus, liver kidney, muscle, intestine and brain. 5-HT2B receptors are responsible for many cardiovascular and central nervous system functions, such as blood vessel contraction, platelet shape changes, neuronal sensitization to tactile stimuli, and mediation of the hallucinogenic effects of phenylisopropylamin hallucinogens.
CD Genomics posted this:DNA & Genomics Sequencing ServiceCD Genomics proprietary GenSeqTM Technology provides advanced multi-omics and bioinformatics service solutions for its global The Specialties of GenSeqTM customers who do research in laboratory. Equipped with the broadest industrial array of cutting-edge technologies and coupled with a group of experienced scientists and bioinformaticians, CD Genomics possesses significant contributions to genetic research.
University of Vigo posted this:Method for the sequential immunochemical evaluation on a same biological sample of NCAM (Neural Cell Adhesion Molecule) protein and its PolySialic Acid (PSA) tail, by western blot coupled to chemiluminiscence detection.The method optimizes the expression assays of PSA-NCAM isoforms in biological samples available in small quantities or restricted (as is the case of human specimens, for example). It improves quantitative and qualitative performance of PSA-NCAM analysis by western blot.
RAMOT at Tel Aviv University Ltd. posted this:A novel behavioral bioassay for preclinical testing and characterization of CNS agentsOur team, including zoologists, statisticians, and computer scientists have developed a new hi-res bioassay for preclinical testing and characterization of CNS agents, extracting key animal-centered parameters of behavior via computerized tracking and measurement of free exploration. The features that distinguish our system and method from other existing systems and methods are: elaborate data preparation for analysis and a methodology that secures replicability of results across laboratories, and exposes active management of kinematic variables. Our measured parameters are carefully designed, animal-centered building blocks of behavior. They are selected on the basis of an in-depth understanding of the mouse’s functional world. These quite unexpected and unusual parameters reflect the animal’s cognitive and emotional state and its information processing capacity; therefore they are most prone to be affected by drugs that act on respective CNS structures that mediate these states. Unlike all other existing systems we expose and quantify the rich and highly organized developmental dynamics of self regulated behavioral growth. The dynamics of this process before and after genetic manipulation and/or pharmacological treatment can now be readily measured by our system, articulating the effects of potential CNS drugs on behavioral growth and decay processes. Project ID : 2-2009-11
RAMOT at Tel Aviv University Ltd. posted this:Oral Mucosa-derived Stem Cells: A Unique Population for the Prevention and Treatment of Ischemic Heart FailureStem cells (SC) are considered crucial building blocks for any regenerative strategy. Adult oral mucosa (OM) is a unique source for generating adult pluripotent stem cell (OPSC) populations. This uniqueness consists in the fact that 95% of the OM whole populations in culture (1st – 8th passages) express markers of embryonic and mesenchymal SC. Thus, in contradistinction to known sources which comprise very low numbers of SC, OPSC generation for clinical use is simple and cost effective and does not require cumbersome cost-consuming purification steps. The general objective is to lay the foundation for the development of a variety of products based on the pluripotency and simple and cost effective generation of billions of OPSC. The major aim of the proposed project is to develop a product for the treatment of ischemic heart failure (IHF). This product which will serve as a proof of concept was selected based on medicals needs, market cap and time to market. The specific aims of the proposal are: 1. To develop a cardiac product aimed at treating ischemic heart failure (IHF). The aim is to test the safety and therapeutic effect of OPSC on experimental IHF in a minipig model. 2. To strengthen the intellectual property by fully characterizing the profile of OPSC. The prevalence of IHF continuously increases (1 million new cases every year in the western world) and currently the market cap is estimated in the range of billions. Project ID : 10-2011-260
RAMOT at Tel Aviv University Ltd. posted this:Immunotherapy for Stroke and Cognition in a Cerebral Amyloid Angiopathy Animal ModelCerebral amyloid angiopathy (CAA) is due to amyloid accumulation in the vessel walls leading to hemorrhagic stroke, and cognitive impairment. There are no available treatments to specifically reduce the risk of CAA. In this research we aim to assess brain tissue damage and cognitive impairment resulting from CAA in animal model and to investigate a novel approach to immune therapy. Methods: We have shown that nasal vaccination with a proteosome adjuvant (Protollin) that is well tolerated in humans, decreases amyloid plaques in an Alzheimer’s disease mouse model. It was recently reported that an overexpression of TGF-?1 under the control of an astrocyte promoter GFAP in mice results in CAA. TGF-?1 mice were nasally treated with Protollin on a weekly basis starting at the age of 13 months for three months. Following treatment animals were subjected for MRI and cognition analysis. Results: Here we show that nasal Protollin activates perivascular macrophage and potently decreases vascular amyloid in TGF-?1 mice. Using MRI we found that while PBS treated animals showed a significant enlargement of the lateral ventricles area, Protollin prevents further brain damage and prevents pathological changes in the blood-brain barrier. Vascular risk factors have been found to be associated with vascular dementia. Using an object recognition test and Y-maze, we found significant improvement in cognition with the Protollin treated group. Interpretation :Our study demonstrates that activation of macrophages by Protollin is a novel approach to reduce microhemorrhage, prevent stroke and improve cognition in a model of cerebral amyloid angiopathy. Project ID : 10-2011-259
Barcelona Skin Genomic posted this:Dermatological pharmaceutical composition for the treatment of skin inflammatory diseases, such as dermatitis and atopic dermatitis (Psoriasis, Acne and Itchy Skin)Dermatological formulation, composed of pharmaceutical compounds, antioxidant molecules and additional active ingredients are developed by Barcelona Skin Genomic to treat inflammatory skin diseases with high efficacy during treatment of atopic dermatitis (AD) with high Scoring Atopic Dermatitis (SCORAD) index, Psoriasis, Acne and Itchy Skin.
Fundació URV posted this:A robust breast cancer computer-aided diagnosis systemWe analyze breast cancer in mammographies, ultrasonographies, magnetic resonance imaging (MRI) and thermographies. Our analysis includes mass/normal breast tissue classification, benign/malignant tumor classification in mammograms and ultrasound images, tumor detection in thermograms, mammogram registration and analysis of the evolution of breast tumors. We also quantify and visualize the evolution of breast tumors in patients undergoing medical treatment. While the previous works mainly focus on analyzing one type of breast images, we implement a robust CAD system for detecting, classifying and studying the evolution of breast cancer. This CAD system analyzes breast cancer in several types of medical images. To implement our CAD system, we use computer vision, pattern recognition and machine learning methods. We also need to collect a large scale breast cancer dataset from hospitals. This dataset should include mammograms, ultrasound, thermograms and MRI images for the same patients. Our CAD gives accurate diagnosis results because it gathers information from different sources.
Barcelona Skin Genomic posted this:Recommendation of optimal combinations of natural active compounds to treat disease using a databaseBarcelona Skin Genomic (BSG) is developing a database that compiles information about the effects of different natural active compounds or plant extracts (more than 2500) on gene expression, on the levels of expression of interleukins and other molecules (more than 3400) and on treatment of different diseases (677). This database collects information from more than 5000 scientific articles, integrated by biologists and experts in life sciences and is updated on a monthly basis.
Centre Technology Transfer CITTRU posted this:Anti-histidine and Anti-arginine Tag DNA aptamers for biotechnological applicationsThe subject of the offer are unique sequences of single-stranded DNA aptamers with high affinity to any molecule (peptide, protein or DNA derivative) containing His-Tag and Arg-Tag and their application in biotechnology in analysis of His-Tagged and Arg-Tagged molecules.
Yissum - Research Development Company of the Hebrew University posted this:Oxidized Cellulose Used to Prevent Allergic Reaction in Asthma, Seasonal Allergies, and Atopic DermatitisA new composition of matter comprising microparticles with both oxidized cellulose and glucans. The composition includes pharmaceutically acceptable carrier and as an active ingredient oxidized cellulose. Preferable the oxidized cellulose should be formed as microparticles and the combimation can be used for the treatment of asthma and allergy. keywords: formulation, allergy Project ID : 7-2006-398
Centre Technology Transfer CITTRU posted this:New method for efficient isolation of microbial DNA from bloodThe method of the invention is a solution that allows the simultaneous isolation of microbial DNA from the blood. In this method the isolation is carried out by compilation of enzymatic, mechanical and thermal lysis. This approach enables to obtain DNA from all types of organisms, irrespective of the structure of the cells.The obtained precipitate is subjected to further preparations, using a commercial DNA isolation kit according to the protocol provided by the manufacturer's procedure. The procedure results in obtaining the DNA ready for further stages of the analysis, e.g. performing a PCR reaction to detect fungi. The most important and most difficult problem in the treatment of bloodstream infections, determining the effectiveness of therapy and, consequently, the cost and time of hospitalization, is the effective diagnosis of factors responsible for the systemic inflammatory response in the course of sepsis. Determination of etiologic factors allows for selection of appropriate antibiotic therapy. The material subjected to diagnostic testing is blood taken from the patient showing clinical signs of sepsis. Currently, the "gold standard" diagnostic method is testing for microbial growth after inoculation in culture media specific to selected pathogen groups. This method is relatively simple and inexpensive, but also time-consuming – results can be available as late as in 5 days. Moreover, identification of pathogens with this method often fails due to low sensitivity; microbial growth can be detected in only about 15-20% of the cultures.
Yissum - Research Development Company of the Hebrew University posted this:Novel Combination Treatment Options for Solid Tumors: Replication-Competent Retroviral Vectors (RCRs) Target Hypoxic Tumor Areas and Increase Sensitivity to ChemotherapyNovel combinatorial treatment options for solid tumors: Replication-competent retroviral vectors (RCRs) target hypoxic tumor areas and increase sensitivity to chemotherapy Replication competent retroviral vectors (RCRs) target hypoxic tumor areas and increase sensitivity to chemotherapy Novel Combinatorial Treatment Options for Metastatic Uveal Melanoma and Hepatocellular Carcinoma Project ID : 6-2016-4274